New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - flumazenil 0.1 mg/ml - solution for injection - 1 mg/10ml - active: flumazenil 0.1 mg/ml excipient: acetic acid disodium edetate dihydrate nitrogen sodium chloride sodium hydroxide water for injection - flumazenil injection is indicated for reversal of the centrally sedative effects of benzodiazepines. it should therefore be used in anaesthesia and intensive care in the following indications: in anaesthesia · termination of general anaesthesia induced and maintained with benzodiazepines in inpatients. · reversal of benzodiazepine sedation in short diagnostic and therapeutic procedures in both inpatients and outpatients. · reversal of paradoxical reactions due to benzodiazepines. in intensive care and in the management of unconsciousness of unknown origin · for the diagnosis and/or management of benzodiazepine overdose due to self-poisoning or accidental overdose. · as a diagnostic measure in unconsciousness of unknown origin to differentiate between involvement of benzodiazepines, other medicines or drugs or brain damage. · may also be used for specific reversal of the central effects of benzodiazepines in drug or medicine overdose (return to spontaneous respiration and consciousness in order to render intubation unnecessary or allow extubation).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - flumazenil, quantity: 0.1 mg/ml - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; disodium edetate; water for injections; glacial acetic acid - flumazenil is indicated for use in hospitalised patients for the reversal of acute benzodiazepine effects (overdose or therapeutic). hospitalised patients are patients admitted to hospital, inpatient care and under continued professional observation while under the influence of flumazenil. not to be used in outpatients or short stay patients. not to be used as a diagnostic.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - flumazenil (unii: 40p7xk9392) (flumazenil - unii:40p7xk9392) - flumazenil injection, usp is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose. flumazenil injection, usp is indicated for the reversal of conscious sedation induced with benzodiazepines (see precautions , pediatric use ). flumazenil injection, usp is contraindicated: • in patients with a known hypersensitivity to flumazenil or benzodiazepines. • in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). • in patients who are showing signs of serious cyclic antidepressant overdose (see warnings ). flumazenil acts as a benzodiazepine antagonist, blocks the effects of benzodiazepines in animals and man, antagonizes benzodiazepi

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - flumazenil 0.1 mg/ml;   - solution for injection - 0.1 mg/ml - active: flumazenil 0.1 mg/ml   excipient: acetic acid disodium edetate 1 n sodium hydroxide solution (adjust the ph to 4.1) nitrogen sodium chloride water for injection - flumazenil is indicated for reversal of the centrally sedative effects of benzodiazepines. it should therefore be used in anaesthesia and intensive care in the following indications: in anaesthesia - termination of general anaesthesia induced and maintained with benzodiazepines in inpatients. - reversal of benzodiazepine sedation in short diagnostic and therapeutic procedures in both inpatients and outpatients. - reversal of paradoxical reactions due to benzodiazepines. in intensive care and in the management of unconsciousness of unknown origin - for the diagnosis and/or management of benzodiazepine overdose due to self-poisoning or accidental overdose. - as a diagnostic measure in unconsciousness of unknown origin to differentiate between involvement of benzodiazepines, other medicines or drugs or brain damage. - flumazenil may also be used for specific reversal of the central effects of benzodiazepines in drug or medicine overdose (return to spontaneous respiration and consciousness in order to render intubation unnecessary or allow extubation).

Canada - English - Health Canada

sandoz canada incorporated - flumazenil - solution - 0.1mg - flumazenil 0.1mg - miscellaneous central nervous system agents

Canada - English - Health Canada

fresenius kabi canada ltd - flumazenil - solution - 0.1mg - flumazenil 0.1mg - miscellaneous central nervous system agents

Canada - English - Health Canada

sandoz canada incorporated - flumazenil - solution - 0.1mg - flumazenil 0.1mg - miscellaneous central nervous system agents

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

hameln pharma ltd - flumazenil - solution for injection - 100microgram/1ml

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - flumazenil 0.1 mg/ml - solution for injection - 0.1 mg/ml - active: flumazenil 0.1 mg/ml excipient: disodium edetate glacial acetic acid sodium chloride sodium hydroxide water for injection - for reversal of the centrally sedative effects of benzodiazepines. it should therefore be used in anaesthesia and intensive care in the following indications: in anaesthesia: -termination of general anaesthesia induced and maintained with benzodiazepines in inpatients. -reversal of benzodiazepine sedation in short diagnostic and therapeutic procedures in both inpatients and outpatients. -reversal of paradoxical reactions due to benzodiazepines. in intensive care and in the management of unconsciousness of unknown origin: -for the diagnosis and/or management of benzodiazepine overdose due to self-poisoning or accidental overdose. -as a diagnostic measure in unconsciousness of unknown origin to differentiate between involvement of benzodiazepines, other medicines or drugs or brain damage. -flumazenil-claris may also be used for specific reversal of the central effects of benzodiazepines in drug or medicine overdose (return to spontaneous respiration and consciousness in order to render intubation unnecessary or allow extubation).

Ireland - English - HPRA (Health Products Regulatory Authority)

b. braun melsungen ag - flumazenil - solution for injection - 0.1 mg/ml